A randomised evaluation of low-dose cytarabine arabinoside plus lenalidomide versus single-agent low-dose cytarabine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 Trial
Authors
Coplan, M.Ariti, C.
Thomas, I.
Upton, L.
Sydenham, M.
Mehta, P.
Islam, S.
Kjeldsen, L.
Burnett, A. K.
Hills, R.
Russell, N. H.
Dennis, Michael
Affiliation
Paul O'Gorman Leukaemia Research Centre, University of Glasgow, GlasgowIssue Date
2021
Metadata
Show full item recordCitation
Coplan M, Ariti C, Thomas I, Upton L, Sydenham M, Mehta P, et al. A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398804290.Journal
BloodDOI
10.1182/blood-2021-147802Additional Links
https://dx.doi.org/10.1182/blood-2021-147802Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147802